Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 88

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 88
---
 strategic alliances or marketing,
distribution or licensing arrangements with third parties, it may be required to relinquish valuable rights to its technologies, future
revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to the Company. If the
Company is unable to raise capital when needed or on acceptable terms, the Company could be forced to delay, reduce or eliminate its
R&D programs or future commercialization efforts.

Cash
Flows

    For
    the Six Months Ended June 30,  

    2024  

    2025
    (Successor)  
    (Pro
    forma, Predecessor and Successor)  
    Difference 

    Net cash used in operating activities 
    $(9,068,702) 
    $(8,617,285) 
    $(451,417)
  
    Net cash provided by
    financing activities: 
     9,044,316  
     9,748,916  
     (704,600)
  
    Net
    (decrease) increase in cash, restricted cash and cash equivalents 
    $(24,386) 
    $1,131,631  
    $(1,156,017)

Net
cash used in operating activities

Net cash used in operating
activities for the six months ended June 30, 2025 primarily reflected a net loss of $10,523,000, adjusted for the reconciliation of non-cash
items such as depreciation expense of $146,000, stock-based compensation of $488,000, stock-based inducement expense of $864,000, and
amortization of right-of-use asset of $391,000, and changes in operating asset and liabilities primarily consisting of an increase in
prepaid expenses and other current assets of $169,000, an increase in accounts payable of $562,000, a decrease in accrued liabilities
of $404,000, and a decrease in operating lease liabilities of $423,000.

Net cash used in operating activities for the six months ended June
30, 2024 primarily reflected a net loss of $4,748,000, adjusted for the reconciliation of non-cash items such as a gain of settlement
of liabilities with vendors of $589,000, depreciation expense of $228,000, stock-based compensation of $1,489,000, amortization of right-of-use
asset of $353,000 and a gain